Transcranial magnetic stimulation (TMS) is a method of non-invasive brain stimulation that affects the cerebral cortex but not deep structures. In patients with movement disorders the most common application of TMS has been to test the excitability of connections within and among motor areas of the cortex, which has provided useful information on pathophysiology; however, inter-individual variability in the responses has resulted in difficulties in translating this method into a clinically applicable diagnostic use. Repeated stimulation (eg, 1 Hz for 20 min) can result in long-term plastic changes in the motor system, which has led to increased interest in possible therapeutic applications. In this Review, we describe the theoretical background to TMS techniques and discuss the uses of TMS as a potential diagnostic tool in movement disorders. The difficulties in bringing the technique into regular clinical diagnostic practice will be discussed and the evidence for the potential of repetitive TMS as a therapeutic tool in patients with movement disorders will be reviewed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1474-4422(08)70190-X | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and validation of the Women Autonomy Scale for measuring psychosocial freedom from conventional gender roles.
BMC Psychol
January 2025
Department of Psychiatry, College of Medicine and Health Sciences, Government Hospitals, Arabian Gulf University, Manama, Bahrain.
Background: The concepts of masculinity and femininity have historically shaped gender roles, leading to inequality and gender-based discrimination. Women's autonomy, defined as the ability to make independent choices across various life domains, remains inadequately measured by existing scales. This study addresses this gap by developing and validating the Women Autonomy Scale (WAS).
View Article and Find Full Text PDFToward a biological definition of neuronal and glial synucleinopathies.
Nat Med
January 2025
Department of Neurology & Neurological Sciences, Stanford Movement Disorders Center, Stanford University, Stanford, CA, USA.
Cerebral accumulation of alpha-synuclein (αSyn) aggregates is the hallmark event in a group of neurodegenerative diseases-collectively called synucleinopathies-which include Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Currently, these are diagnosed by their clinical symptoms and definitively confirmed postmortem by the presence of αSyn deposits in the brain. Here, we summarize the drawbacks of the current clinical definition of synucleinopathies and outline the rationale for moving toward an earlier, biology-anchored definition of these disorders, with or without the presence of clinical symptoms.
View Article and Find Full Text PDFAuthor Correction: MRgFUS subthalamotomy in Parkinson's disease: an approach aimed at minimizing Lesion Volume.
NPJ Parkinsons Dis
January 2025
Movement Disorders Unit, Department of Neurology, Hospital La Fe, Valencia, Spain.
Rapid acclimatization to baseline stimulation with a multi-canal vestibulocochlear implant.
Eur Arch Otorhinolaryngol
January 2025
Department of Otorhinolaryngology and Head and Neck Surgery, Division of Balance Disorders, School for Mental Health and Neuroscience (MHENS), Maastricht University Medical Centre, Maastricht, The Netherlands.
Purpose: It is hypothesized that a vestibular implant should re-establish baseline activity of the ampullary nerves. Use of a constant baseline stimulation potentially allows encoding of bi-directional head movements, through the addition of signal modulations. Effective stimulation of the vestibular nerves depends on the ability to acclimate to this baseline signal.
View Article and Find Full Text PDFBehavioral, biochemical, and molecular characterization of MPTP/p-intoxicated mice.
Exp Neurol
January 2025
Guangdong Key Laboratory of Age-Related Cardiac and Cerebral Diseases, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China; The Marine Biomedical Research Institute of Guangdong, School of Ocean and Tropical Medicine, Guangdong Medical University, Zhanjiang 524000, China. Electronic address:
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model remains the most extensively utilized animal model for Parkinson's disease (PD). Treatment regimens are classified into three categories: acute, subacute, and chronic. Among these, the MPTP with probenecid (MPTP/p)-induced chronic mouse model is favored for its capacity to sustain long-term striatal dopamine depletion, though the resultant behavioral, biochemical, and molecular alterations require further validation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!